Real World Bleeding Risks in Non-valvular Atrial Fibrillation Patients With Heart Failure: Contemporary EHR Results Among Prescribed Apixaban, Dabigatran, Rivaroxaban and Warfarin

被引：0
|
作者：
Lin, Iris
Horblyuk, Ruslan
Mardekian, Jack
Park, Sang Hee
Kamble, Shital
Hamilton, Melissa
Abdulsattar, Younos
Petkun, William
Menzin, Joseph
Lip, Gregory Y.
机构：
来源：
CIRCULATION | 2016年 / 134卷
关键词：
Atrial fibrillation; Anticoagulants; Warfarin; Hemorrhage; Outcomes;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
13828
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Contemporary results from EHR study of real-world bleeding risk among elderly and overall non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, rivaroxaban and warfarin
    Lin, I.
    Masseria, C.
    Mardekian, J.
    Park, S.
    Horblyuk, R.
    Kamble, S.
    Hamilton, M.
    Abdulsattar, Y.
    Petkun, W.
    Menzin, J.
    Lip, G. Y. H.
    EUROPEAN HEART JOURNAL, 2016, 37 : 235 - 236
  • [2] Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban
    Tepper, Ping G.
    Mardekian, Jack
    Masseria, Cristina
    Phatak, Hemant
    Kamble, Shital
    Abdulsattar, Younos
    Petkun, William
    Lip, Gregory Y. H.
    PLOS ONE, 2018, 13 (11):
  • [3] BLEEDING RISK AMONG JAPANESE NON-VALVULAR ATRIAL FIBRILLATION PATIENTS INITIATED ON APIXABAN, DABIGATRAN, RIVAROXABAN OR WARFARIN IN THE REAL WORLD
    Wang, Feng
    Murata, Tatsunori
    Izumi, Naoko
    Kida, Makoto
    Horblyuk, Ruslan
    Terayama, Yasuo
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 443 - 443
  • [4] Risk of major bleeding among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, rivaroxaban, or warfarin in the US Medicare population
    Amin, A.
    Keshishian, A.
    Trocio, J.
    Dina, O.
    Le, H.
    Rosenblatt, L.
    Mardekian, J.
    Zhang, Q.
    Baser, O.
    Liu, X.
    Vo, L.
    EUROPEAN HEART JOURNAL, 2017, 38 : 964 - 964
  • [5] Real world comparison of major bleeding risk among non-valvular atrial fibrillation patients newly initiated on apixaban, dabigatran, rivaroxaban or warfarin
    Lip, G. Y. H.
    Pan, X.
    Kamble, S.
    Kawabata, H.
    Mardekian, J.
    Masseria, C.
    Bruno, A.
    Phatak, H.
    EUROPEAN HEART JOURNAL, 2015, 36 : 1085 - 1085
  • [6] Real-world bleeding risk among non-valvular atrial fibrillation (NVAF) patients prescribed apixaban, dabigatran, rivaroxaban and warfarin: analysis of electronic health records
    Lin, I.
    Masseria, C.
    Mardekian, J.
    Frean, M.
    Phatak, H.
    Kamble, S.
    Abdulsattar, Y.
    Petkun, W.
    Menzin, J.
    Lip, G. Y. H.
    EUROPEAN HEART JOURNAL, 2015, 36 : 1084 - 1084
  • [7] Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients on apixaban, dabigatran, rivaroxaban: cohorts comprising new initiators and/or switchers from warfarin
    Tepper, P.
    Mardekian, J.
    Masseria, C.
    Phatak, H.
    Kamble, S.
    Abdulsattar, Y.
    Petkun, W.
    Lip, G. Y. H.
    EUROPEAN HEART JOURNAL, 2015, 36 : 339 - 339
  • [8] REAL-WORLD COMPARISON OF MAJOR BLEEDING RISK AMONG UNTREATED NON-VALVULAR ATRIAL FIBRILLATION PATIENTS AND THOSE INITIATING APIXABAN, DABIGATRAN, RIVAROXABAN, OR WARFARIN
    Amin, Alpesh
    Keshishian, Allison
    Xie, Lin
    Baser, Onur
    Price, Kwanza
    Vo, Lien
    Mardekian, Jack
    Mendoza, Mario
    Singhal, Shalabh
    Patel, Chad
    Odell, Kevin
    Trocio, Jeffrey
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 668 - 668
  • [9] Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States
    Lip, Gregory Y. H.
    Pan, Xianying
    Kamble, Shital
    Kawabata, Hugh
    Mardekian, Jack
    Masseria, Cristina
    Bruno, Amanda
    Phatak, Hemant
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2016, 70 (09) : 752 - 763
  • [10] Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin A propensity score matched analysis
    Lip, Gregory Y. H.
    Keshishian, Allison
    Kamble, Shital
    Pan, Xianying
    Mardekian, Jack
    Horblyuk, Ruslan
    Hamilton, Melissa
    THROMBOSIS AND HAEMOSTASIS, 2016, 116 (05) : 975 - 986
12345